Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ABI-5366

Small molecule · developed by Assembly Biosciences

Phase 1 Most advanced trial (none active)

ASMB Developer

1 Registered trials

What is ABI-5366?

ABI-5366 is an orally administered tablet studied in recurrent genital herpes simplex virus type 2 infection.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Therapy area: Infectious disease
Developer: Assembly Biosciences (ASMB)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06385327	Phase 1	Recurrent Genital Herpes Simplex Type 2	Completed	ASMB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Recurrent Genital Herpes Simplex Type 2

More from Assembly Biosciences

ABI-1179 Phase 1 ABI-4334 Phase 1 ABI-6250 Phase 2 ABI-H2158 Phase 2 ABI-H3733 Phase 1 ABI-M201 Phase 1 Peg-IFNα Phase 2 Vebicorvir Phase 2

Sources

ClinicalTrials.gov NCT06385327

Updated Oct 11, 2026. Something wrong or missing? Report it on the ASMB page.

Follow ASMB, the company behind ABI-5366

See ASMB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ASMB catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z